Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | IL2 | P60568 | 7/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2306036 | 0.99 | RAB9A (0.56) | RAB9ANPC1MEN1KMT2AIL2 | |
| SCHEMBL2310680 | 0.90 | IL2 (0.54) | RAB9ANPC1MEN1KMT2AIL2 | |
| SCHEMBL4768204 | 0.87 | IL2 (0.60) | IL2LMNAABL1 | |
| SCHEMBL2313330 | 0.86 | IL2 (0.57) | RAB9ANPC1IL2CYP19A1ATM | |
| SCHEMBL2845664 | 0.86 | IL2 (0.52) | RAB9ANPC1IL2LMNATDP1 | |
| SCHEMBL4764385 | 0.85 | IL2 (0.58) | RAB9ANPC1MEN1KMT2AIL2 | |
| SCHEMBL4771746 | 0.81 | IL2 (0.55) | MEN1KMT2AIL2 | |
| SCHEMBL4766353 | 0.80 | IL2 (0.63) | MEN1KMT2AIL2LMNA | |
| SCHEMBL4764710 | 0.79 | IL2 (0.58) | MEN1KMT2AIL2ABL1 | |
| SCHEMBL2817020 | 0.79 | LMNA (0.55) | IL2LMNAABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196838-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-02 | — | — | US | claimed |
| EP-2350006-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corp. (US) | 2011-08-03 | — | — | EP | claimed |
| US-20100130522-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | claimed |
| WO-2010039238-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-08 | — | — | WO | claimed |
| US-20140045861-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045861-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20120196838-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196838-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20100130522-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130522-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130522-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196838-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCL8, CCR9 | RAB9A 1721/4885NPC1 190/4885MEN1 3704/4885 |
| US-20100130522-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCL8, CCR9 | RAB9A 1721/4885NPC1 190/4885MEN1 3704/4885 |
| US-20140045861-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCL8, CCR9 | RAB9A 1721/4885NPC1 190/4885MEN1 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.